The government’s Regulatory Reform Promotion Council on December 22 compiled a paper listing near-term regulatory reform initiatives and proposals, calling for deregulations to facilitate clinical trials and revise the review process for software as a medical device (SaMD). In the…
To read the full story
Related Article
- Industry Calls for Simplifying Regulatory Process for SaMD
October 26, 2021
- Deregulation Panel Prods Govt to Fuel SaMD Development
June 3, 2021
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





